15 June 2026

38 days to PCAC. Zero vacancy appointments in 29 weeks. Roster: 3 voting (Fensky, Rebello, Serumaga) + 1 industry liaison, no chair, of 12 authorized. Oral presentation deadline June 30 (15 days). Historian: Kennedy has filled CDC ACIP, vaccine panels, and other HHS advisory bodies — PCAC inaction is now the longest-unfilled advisory committee under his tenure, strengthening the "deliberate deferral to career staff" reference class over "bureaucratic delay." Skeptic: the counter-narrative (batch-fill before July 9) requires Kennedy to act in a domain where he has shown zero activity for 29 consecutive weeks. Bayesian: prior 0.55, no new evidence either direction, holding. Augur: the FDA 503B exclusion comment period closing June 29 — one day before the oral deadline — creates a regulatory-calendar collision. If major compounding industry pushback materializes in comments, it could influence PCAC tone. Stoic: NOISE — unactionable until vacancy announcement or oral deadline passes. Premortem rotated to medicare-glp1-bridge-uptake this week.

Same vacancy dynamics. Binary-outcome structural concern: 3-member panel → all-pass or all-defer more likely than moderate 2-of-4. Pre-commitment to adjust toward 0.50 if vacancies unfilled by oral deadline June 30 — 15 days. The 503B comment-period collision (June 29) may generate industry submissions that contextualize the 503A decision. Stoic: NOISE — wait for June 30 checkpoint.

Month 18 post-facility-acquisition — now at the lower bound of the 18–24mo base rate for M&A-to-launch. OneTwenty 5+ weeks live with zero FDA enforcement, well past the 30-day regulatory-forbearance threshold. Seeking Alpha retail narrative, TIKR $20B framing, WaPo factory tour all center launch at Aug–Nov 2026. Hims guidance raised to $2.8–3.0B, 125K Wegovy shipments in first 6 weeks. Historian: M&A-to-launch base rate for DTC health companies with acquired facilities is 14–22 months; month 18 is the median. Skeptic: Q1 net loss $92.1M and PCAC deferral could force delay, but management raised guidance and Novo partnership validates branded channel. Bayesian: prior 0.85, no new disconfirming evidence, enforcement silence is mildly confirming → holding at 0.85. Stoic: ACTIONABLE — next catalyst PCAC July 23, then Q2 earnings August. If PCAC defers, Hims may launch peptides anyway under regulatory forbearance already established by OneTwenty precedent.

No new adverse events. Eli Lilly issued a warning about fraudulent compounded tirzepatide containing bacteria, high impurity levels, incorrect chemical structures, and sugar alcohol. This is not a peptide incident per se (GLP-1 compounding ≠ research peptides) but establishes the "named pharma company documents contamination" template. FDA received 455+ adverse event reports on compounded semaglutide and 320+ on compounded tirzepatide. DOJ enforcement infrastructure (Tailor Made, Watkins, Peptide Sciences) continues. Post-ADA / pre-PCAC media window Day 7 of 44. Nature citation pipeline active. Historian: Lilly's contamination warning follows the pattern of branded pharma documenting safety failures in the compounding market — reference class is the 2012 NECC meningitis outbreak (fungal contamination → New England Compounding Center → 76 deaths → DQSA). That was a mass-casualty event; current signals lack a named victim. Skeptic: 289 days remain; the denominator (time × adoption velocity × contamination rate) makes eventual coverage likely even without a mass event — but "by March 2027" requires the trigger event to occur in the next 9 months. Bayesian: Lilly warning is a +0.02 signal (institutional documentation, not consumer harm). Holding 0.73. Stoic: unactionable — monitor.

T-15 pre-committed checkpoint. T-16 to July 1 launch. New evidence this week: (1) CMS confirmed no registration, no opt-in required — reduces enrollment friction vs. standard Part D programs. (2) Prior auth form live and operational. (3) CMS confirmed nationwide all-state availability from Day 1. (4) AMCP FAQ published with full operational details. (5) Humana central processor is the sole prior auth pathway — single point of failure. Historian: reference class is new Part D programs. The closest analogue is the 2006 Part D launch itself (25M enrolled in Year 1 vs 43M eligible = 58% uptake) but that was the entire Part D benefit, not a single-drug demonstration. More apt: Medicare Diabetes Prevention Program (MDPP, 2018 launch) hit ~4,000 suppliers in Year 1 but enrollment data was never published as a clean number. The "under 1M" bar is low enough that historical Part D demonstrations suggest it's more likely under than over — new programs are slow. Skeptic: the counter-narrative (>1M by Dec 31) requires >167K enrollments/month across 6 months with a single Humana processor handling all prior auths. If Humana processes at 10K/day capacity, theoretical max is ~1.8M in 6 months — so the physical capacity exists. The question is physician awareness + patient demand velocity. Bayesian: prior 0.73. New evidence: operational infrastructure is slightly more mature than expected (no-opt-in, form live, FAQ published), which marginally reduces friction. But Humana bottleneck persists. Posterior: 0.75 (+0.02). Stoic: ACTIONABLE — glp1picks Bridge content must be production-ready by July 1. June 30 is the last day for SEO indexation pre-launch. PREMORTEM (medicare-glp1-bridge-uptake): The forecast is proven catastrophically wrong — more than 1M Medicare beneficiaries enroll by December 31. What would have had to be true: CMS aggressively markets the Bridge to the 14M eligible population with direct mailers (they've done this before with Part D LIS); major PBMs pre-populate formulary flags so physicians see Bridge eligibility at point of prescribing; pent-up demand among 65+ obese patients who've watched younger patients on GLP-1s creates a first-month surge analogous to iPhone launch-week dynamics. Latent condition already present: CMS's "no opt-in required" framing is structurally identical to auto-enrollment — the only barrier is prior auth, not patient action. This reduces friction below the reference class. Implication: if Humana scales processing beyond 10K/day (automated adjudication, not manual review), the 1M ceiling is physically breakable. The 0.75 posterior may be 0.03-0.05 too high.

No peptide DTC affiliate programs launched. GLP-1 pipeline continues deepening: CagriSema PDUFA expected October 2026, retatrutide NDA filing expected H2 2026, MariTide Phase 3 ongoing. Each new branded molecule creates another $260+ CPA referral pathway. glp1picks GSC: impressions 1,122 (↓65%), clicks 17 (↓56%), position 18.4. Eleventh consecutive declining week for Google organic but CTR improved to 1.52%. Katalys: 273 clicks (+6% WoW), 1 conversion, $500 payout — SkinnyRx concentration. Historian: no structural analogue for DTC peptide affiliate programs emerging before PCAC outcome is known. Skeptic: if Hims launches peptides with a $200+ CPA referral program, the math inverts — but that requires both launch AND affiliate program in 6.5 months. Bayesian: holding 0.85. Stoic: ACTIONABLE — glp1picks backlink strategy (DR 1.7) is the binding lever for organic recovery; CPA math holds regardless of traffic level.